Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -2.66% is 32% above its 1-year average of -3.93%, around the middle of its 1-year range (-10.72%–1.04%).
2.81% below its 12-month average of -2.59%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 1.04%.
NET PROFIT MARGIN
-2.66%
NET PROFIT MARGIN AVG TTM
-2.59%
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2.81%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 683 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Lumexa Imaging Holdings, Inc. Common Stock
Market Cap
$1.02B
Net Profit Margin
-2.66%
TTM Avg
-2.59%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.03B
Net Profit Margin
-0.44%
TTM Avg
-16.00%
3Y Avg
-4.01%
5Y Avg
0.78%
Market Cap
$1.04B
Net Profit Margin
-493.26%
TTM Avg
-198.62%
3Y Avg
-139.13%
5Y Avg
-250.17%
Market Cap
$1.00B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.04B
Net Profit Margin
-5.43%
TTM Avg
-0.76%
3Y Avg
-19.17%
5Y Avg
-21.06%
Market Cap
$1.01B
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$997.80M
Net Profit Margin
19.87%
TTM Avg
-292.21%
3Y Avg
-499.51%
5Y Avg
-430.28%
Market Cap
$997.31M
Net Profit Margin
-32.54%
TTM Avg
-35.87%
3Y Avg
-66.42%
5Y Avg
-187.72%
Market Cap
$997.28M
Net Profit Margin
-727.04%
TTM Avg
-1969.28%
3Y Avg
-984.64%
5Y Avg
-984.64%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI) | $1.02B | -2.66% | -2.59% | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | -0.44% | -16.00% | -4.01% | 0.78% |
| Immatics N.V. (IMTX)vs › | $1.04B | -493.26% | -198.62% | -139.13% | -250.17% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $1.00B | 0.00% | 0.00% | 0.00% | 0.00% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | -5.43% | -0.76% | -19.17% | -21.06% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $997.80M | 19.87% | -292.21% | -499.51% | -430.28% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $997.31M | -32.54% | -35.87% | -66.42% | -187.72% |
| Aktis Oncology, Inc. (AKTS)vs › | $997.28M | -727.04% | -1969.28% | -984.64% | -984.64% |
| Pacira BioSciences, Inc. (PCRX)vs › | $991.05M | 1.96% | -6.61% | -1.16% | 6.17% |
Operating Margin
1.4%
Net Profit Margin
-2.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 1.04% |
| 2026-03-31 | 0.68% |
| 2025-12-31 | -10.72% |
| 2025-09-30 | -1.35% |
| 2025-03-31 | -3.14% |
| 2024-12-31 | -10.10% |
